![](https://monteverdelaw.com/wp-content/uploads/Screenshot-2024-08-09-111836.png)
G1 Therapeutics, Inc. (Nasdaq: GTHX), relating to its proposed merger with Kahn Swick & Foti, LLC (“KSF”). Under the terms of the proposal, KSF will commence a tender offer to purchase GTHX stock at a price of $7.15 per share.
G1 Therapeutics, Inc. (Nasdaq: GTHX), relating to its proposed merger with Kahn Swick & Foti, LLC (“KSF”). Under the terms of the proposal, KSF will commence a tender offer to purchase GTHX stock at a price of $7.15 per share.